ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase A, members will acquire different doses and schedules of oral ABBV-744 pill to discover Risk-free dosing regimen. Additional contributors are going to be enrolled for the identified monotherapy dosign routine. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "insert-on" therapy. In Segment C, c